BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jin A, Yang Y, Su X, Yang W, Liu T, Chen W, Li T, Ding L, Wang H, Wang B, Pan B, Zhou J, Fan J, Yang X, Guo W. High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. Clinical Laboratory Analysis. [DOI: 10.1002/jcla.24259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee B, Kim J, Kang K, Lee S, Park Y, Sung H, Kim B. PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma. Biomedicines 2022;10:1099. [DOI: 10.3390/biomedicines10051099] [Reference Citation Analysis]
2 Karamali N, Ebrahimnezhad S, Khaleghi Moghadam R, Daneshfar N, Rezaiemanesh A. HRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancer. Life Sci 2022;301:120620. [PMID: 35533759 DOI: 10.1016/j.lfs.2022.120620] [Reference Citation Analysis]
3 Zhan M, Zhang Z, Zhao X, Zhang Y, Liu T, Lu L, Li XY. CD155 in tumor progression and targeted therapy. Cancer Lett 2022;:215830. [PMID: 35870689 DOI: 10.1016/j.canlet.2022.215830] [Reference Citation Analysis]